| CAS NO: | 211735-76-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 231.26 |
|---|---|
| Formula | C12H13N3O2 |
| CAS No. | 211735-76-1 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: ≥ 30 mg/mL |
| Water: | |
| Ethanol: | |
| Chemical Name | 1-(2,1,3-Benzoxadiazol-5-ylcarbonyl)piperidine |
| Synonyms | Org-24448; Org 24448; Org24448; CX-691; CX691; CX 691 |
| SMILES Code | O=C(N1CCCCC1)C2=CC3=NON=C3C=C2 |
| In Vitro | In vitro activity: Farampator (also known as CX-691 or Org24448) is a positive and allosteric modulator of the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid) receptor. Kinase Assay: The objective of the study was to investigate the effect of an AMPA positive modulator, CX691, 1) brain-derived neurotrophic factor (BDNF) messenger RNA (mRNA) expression in the rat hippocampus following acute and sub-chronic administration; 2) on neurochemistry in the dorsal hippocampus and medial prefrontal cortex following acute administration. Cell Assay: |
|---|---|
| In Vivo | CX691 attenuated a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improved attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.). Thus, Farampator may have utility for the treatment of cognitive impairment such as such as Alzheimer's disease and schizophrenia. |
| Animal model | Three rodent models of learning and memory |
| Formulation & Dosage | 0.1-1.0 mg/kg; p.o. |
| References | Psychopharmacology (Berl). 2009 Jan;202(1-3):343-54. |
m.cnreagent.com